Community post

What's the path forward when it comes to phage therapy? According to Shawna McCallin of the University Hospital of Geneva and Phages4All, clinical data is the priority, but it won't be enough.

"The recent bankruptcy of Achaogen, a biotech producing a clinically-proven antimicrobial, is reason to heed caution that proof-of-efficacy is not enough to ensure viable commercialization.”

Read Shawna's perspective piece here, and chat with her in person next month at Phage Futures EU in Brussels! (Use registration code PD10 for 10% off!)